WO2007100623A3 - Hydroxylamines et dérivés pour l'inhibition de l'activation du complément - Google Patents

Hydroxylamines et dérivés pour l'inhibition de l'activation du complément Download PDF

Info

Publication number
WO2007100623A3
WO2007100623A3 PCT/US2007/004658 US2007004658W WO2007100623A3 WO 2007100623 A3 WO2007100623 A3 WO 2007100623A3 US 2007004658 W US2007004658 W US 2007004658W WO 2007100623 A3 WO2007100623 A3 WO 2007100623A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibition
complement activation
derivatives
hydroxylamines
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/004658
Other languages
English (en)
Other versions
WO2007100623A2 (fr
Inventor
William L Matier
Ghanshyam Patil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Othera Holding Inc
Original Assignee
Othera Holding Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/677,462 external-priority patent/US20070203190A1/en
Application filed by Othera Holding Inc filed Critical Othera Holding Inc
Priority to JP2008556427A priority Critical patent/JP2009527565A/ja
Priority to EP07751423A priority patent/EP1996195A4/fr
Priority to AU2007221271A priority patent/AU2007221271A1/en
Priority to CA002640738A priority patent/CA2640738A1/fr
Publication of WO2007100623A2 publication Critical patent/WO2007100623A2/fr
Priority to IL193121A priority patent/IL193121A0/en
Anticipated expiration legal-status Critical
Publication of WO2007100623A3 publication Critical patent/WO2007100623A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La présente invention concerne des procédés d'inhibition de l'activation du complément, pour le traitement de pathologies à médiation par un complément, ainsi que pour le traitement de pathologies à médiation par un corps colloïde. Les procédés font appel à des composés d'hydroxylamine et des dérivés esters de ceux-ci, administrés à des sujets en des quantités efficaces.
PCT/US2007/004658 2006-02-22 2007-02-22 Hydroxylamines et dérivés pour l'inhibition de l'activation du complément Ceased WO2007100623A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2008556427A JP2009527565A (ja) 2006-02-22 2007-02-22 補体活性化を阻害するヒドロキシルアミンおよび誘導体
EP07751423A EP1996195A4 (fr) 2006-02-22 2007-02-22 Hydroxylamines et dérivés pour l'inhibition de l'activation du complément
AU2007221271A AU2007221271A1 (en) 2006-02-22 2007-02-22 Hydroxylamines and derivatives for the inhibition of complement activation
CA002640738A CA2640738A1 (fr) 2006-02-22 2007-02-22 Hydroxylamines et derives pour l'inhibition de l'activation du complement
IL193121A IL193121A0 (en) 2006-02-22 2008-07-29 Pharmaceutical compositions containing a hydroxylamine derivatives

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US77547806P 2006-02-22 2006-02-22
US60/775,478 2006-02-22
US11/677,462 2007-02-21
US11/677,462 US20070203190A1 (en) 2006-02-22 2007-02-21 Hydroxylamines and derivatives for the inhibition of complement activation

Publications (2)

Publication Number Publication Date
WO2007100623A2 WO2007100623A2 (fr) 2007-09-07
WO2007100623A3 true WO2007100623A3 (fr) 2008-08-28

Family

ID=38459553

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/004658 Ceased WO2007100623A2 (fr) 2006-02-22 2007-02-22 Hydroxylamines et dérivés pour l'inhibition de l'activation du complément

Country Status (6)

Country Link
EP (1) EP1996195A4 (fr)
JP (1) JP2009527565A (fr)
AU (1) AU2007221271A1 (fr)
CA (1) CA2640738A1 (fr)
IL (1) IL193121A0 (fr)
WO (1) WO2007100623A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981548A (en) * 1994-11-15 1999-11-09 Moreno Paolini N-Hydroxypiperidines as superoxide radicals scavengers
WO2005051328A2 (fr) * 2003-11-20 2005-06-09 Othera Pharmaceuticals, Inc. Amelioration de la degenerescence maculaire et d'autres maladies ophtalmiques

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999037149A1 (fr) * 1998-01-27 1999-07-29 Brigham & Women's Hospital Procede de traitement des lesions cytotoxiques
EP1689354A4 (fr) * 2003-11-20 2010-07-14 Othera Holding Inc Amelioration de la cataracte, de la degenerescence maculaire et autres maladies ophtalmiques
US20090209581A1 (en) * 2005-02-02 2009-08-20 Louis Habash Nitroxides for use in treating or preventing immunological diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981548A (en) * 1994-11-15 1999-11-09 Moreno Paolini N-Hydroxypiperidines as superoxide radicals scavengers
WO2005051328A2 (fr) * 2003-11-20 2005-06-09 Othera Pharmaceuticals, Inc. Amelioration de la degenerescence maculaire et d'autres maladies ophtalmiques

Also Published As

Publication number Publication date
JP2009527565A (ja) 2009-07-30
EP1996195A4 (fr) 2009-08-12
WO2007100623A2 (fr) 2007-09-07
IL193121A0 (en) 2009-08-03
EP1996195A2 (fr) 2008-12-03
CA2640738A1 (fr) 2007-09-07
AU2007221271A1 (en) 2007-09-07

Similar Documents

Publication Publication Date Title
PT2040713E (pt) Para a prevenção ou o tratamento de doenças ou estados clínicos mediados por fxr
WO2010088518A3 (fr) Modulateurs hétérocycliques du gpr119 pour le traitement de maladies
WO2009117421A3 (fr) Modulateurs hétérocycliques de gpr119 pour le traitement d’une maladie
WO2009064460A3 (fr) Systèmes de délivrance aux voies gastro-intestinales
WO2009049184A9 (fr) Administration systémique d'agents de chlorotoxine pour le diagnostic et le traitement de tumeurs
EP2214770A4 (fr) Procédés, kits et compositions pour administrer des composés pharmaceutiques
IL225198A (en) Aminotetrahydropyrenic Compounds, Pharmaceutical Preparations Containing Them and Their Use in the Treatment of Diabetes
WO2007115305A3 (fr) Formes de dosage orales incluant un inhibiteur de l'agrégation plaquettaire et un inhibiteur acide
WO2008021368A3 (fr) Compositions et méthodes de neuroprotection
WO2008022974A3 (fr) Composition antidiabetique contenant de l'acide chicorique et/ou l'un de ses metabolites
WO2008103613A3 (fr) Composés d'hydroxylamine et leurs procédés d'utilisation
WO2008070268A3 (fr) Compositions pharmaceutiques
ZA201001264B (en) 1-amino-alkylcycohxane derivatives for the treatment of cochleat tinnitus
WO2009120919A3 (fr) Formes galéniques de fénofibrate
WO2009071689A3 (fr) Dérivés d'oxindole substitués par halogène en position 5 et leur utilisation pour traiter des maladies liées à la vasopressine
WO2011014825A3 (fr) Petites molécules anti-angiogéniques et procédés d'utilisation
WO2008052139A3 (fr) Doxepine à dose ultrafaible, et ses procédés d'utilisation pour traiter des troubles du sommeil
WO2007106884A3 (fr) Méthodes de traitement des maladies d'atrophie musculaire au moyen d'inhibiteurs de l'activation de nf-kb
WO2007136741A3 (fr) N-desméthyldoxépine et procédés pour traiter les troubles du sommeil l'utilisant
WO2008070010A3 (fr) Rétablissement après une attaque
EP2012807A4 (fr) Composition pharmaceutique d'entérosorbant et de prébiotiques, formes galéniques et procédé pour la prévention et le traitement de troubles gastrointestinaux
WO2007081878A8 (fr) Voies d'indoléamine 2,3-dioxygénase dans la production de lymphocytes t régulateurs
IL192933A0 (en) Benzoisoindole derivatives for the treatment of pain
WO2010042212A3 (fr) Méthodes de traitement prophylactique ou thérapeutique de la douleur à l'aide de dérivés de spicamycine
WO2008094054A3 (fr) Composés

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 193121

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2640738

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 200780006439.3

Country of ref document: CN

Ref document number: 2008556427

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007221271

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007751423

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2007221271

Country of ref document: AU

Date of ref document: 20070222

Kind code of ref document: A